Ocera Therapeutics Reports Second Quarter 2015 Financial Results
03 août 2015 16h13 HE
|
Ocera Therapeutics, Inc.
Continued Strong Enrollment in STOP-HE On Track for Initiation of Phase 1 Trial with Oral Formulation of OCR-002 in Third Quarter $20 Million Debt Facility Extends Cash Resources to Mid-2017 PALO...
Ocera Therapeutics to Present at the Jefferies 2015 Healthcare Conference
29 mai 2015 13h30 HE
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif., May 29, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today...
Ocera Reports Pipeline Progress and First Quarter 2015 Financial Results
30 avr. 2015 08h05 HE
|
Ocera Therapeutics, Inc.
Strong Enrollment in STOP-HE Trial
Conference Call and Webcast at 10:00 a.m. ET
PALO ALTO, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage...
Ocera Therapeutics to Report Pipeline Progress and First Quarter 2015 Financial Results
22 avr. 2015 16h43 HE
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif., April 22, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today...
Ocera Completes Interim Analysis of OCR-002 in Phase 2b STOP-HE Study for the Treatment of Acute Hepatic Encephalopathy
01 avr. 2015 17h03 HE
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif., April 1, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today...
Ocera Reports Fourth Quarter and Full Year 2014 Financial Results
11 mars 2015 16h01 HE
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif., March 11, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today...
Ocera Therapeutics Promotes Michael Byrnes to Chief Financial Officer
03 déc. 2014 08h01 HE
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif., Dec. 3, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical-stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today...
Ocera Reports Third Quarter 2014 Financial Results
13 nov. 2014 16h05 HE
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today...
Ocera Therapeutics to Present at Stifel 2014 Healthcare Conference
10 nov. 2014 08h05 HE
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today...
Ocera Therapeutics to Announce Third Quarter 2014 Financial Results
04 nov. 2014 16h05 HE
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif., Nov. 4, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today...